Roger B. Ruggeri
Papers
1
Total Citations
32
H-Index
1
About
Roger B. Ruggeri has made transformative contributions to cardiovascular drug discovery, with his work centering on the inhibition of microsomal triglyceride transfer protein (MTP) as a powerful strategy for lowering low-density lipoprotein (LDL) cholesterol. His most cited paper, a 2002 study with 32 citations, details the discovery of clinically active MTP inhibitors through high-throughput screening and parallel synthesis paradigms. This research demonstrated that blocking MTP effectively halts hepatic secretion of VLDL and intestinal secretion of chylomicrons, establishing a highly efficacious pharmacological target for dyslipidemia. Ruggeri’s innovative approach bridged medicinal chemistry and translational pharmacology, paving the way for novel lipid-lowering therapies. His achievements highlight a career dedicated to tackling metabolic disease through mechanism-based drug design, offering a compelling example of how targeted enzyme inhibition can yield profound therapeutic impact. For students and researchers, Ruggeri’s work underscores the power of integrating screening technologies with synthetic chemistry to address unmet clinical needs in cardiovascular health.
Research Focus
Key Achievements
Top Papers
- 1